Details for Patent: 8,748,382
✉ Email this page to a colleague
Which drugs does patent 8,748,382 protect, and when does it expire?
Patent 8,748,382 protects TYMLOS and is included in one NDA.
This patent has forty-two patent family members in twenty-eight countries.
Summary for Patent: 8,748,382
| Title: | Method of drug delivery for bone anabolic protein |
| Abstract: | The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients. |
| Inventor(s): | Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle |
| Assignee: | Ipsen Pharma SAS , Radius Health Inc |
| Application Number: | US13/438,086 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,748,382 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,748,382
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | 8,748,382 | ⤷ Start Trial | TREATMENT TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE | ⤷ Start Trial | ||||
| Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | 8,748,382 | ⤷ Start Trial | METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,748,382
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2073789 | ⤷ Start Trial | 301235 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2073789 | ⤷ Start Trial | CA 2023 00019 | Denmark | ⤷ Start Trial |
| European Patent Office | 2073789 | ⤷ Start Trial | 2023C/523 | Belgium | ⤷ Start Trial |
| European Patent Office | 2073789 | ⤷ Start Trial | LUC00309 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2073789 | ⤷ Start Trial | 23/2023 | Austria | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
